title: Role of the MMP9 gene in hemorrhagic transformations after tissue-type plasminogen activator treatment in stroke patients.
abstract: OBJECTIVE
  Despite the benefits of tissue-type plasminogen activator treatment, some stroke patients experience adverse hemorrhagic transformations (HT). Plasma protein levels of MMP9 have been associated with HT occurrence. We aimed to analyze the association of the MMP9 gene with HT occurrence.
  
  
  METHODS
  We analyzed the MMP9 gene in blood samples from 885 stroke patients treated with tissue-type plasminogen activator by tag-SNP, imputed SNP, direct sequencing, and RNA expression.
  
  
  RESULTS
  We did not observe any significant association between MMP9 genetic variations or MMP9 expression and HT occurrence. Moreover, no association was found between MMP9 expression and MMP9 polymorphisms.
  
  
  CONCLUSIONS
  Genetic variations in the MMP9 gene are not associated with HT occurrence in tissue-type plasminogen activator-treated patients.
authors.affiliation: Neurovascular Research Laboratory, Institut de Recerca Vall d'Hebron, Barcelona, Spain.
authors.forename: Israel
authors.initials: I
authors.lastname: Fernández-Cadenas
authors.forename: Alberto
authors.initials: A
authors.lastname: Del Río-Espínola
authors.forename: Caty
authors.initials: C
authors.lastname: Carrera
authors.forename: Sophie
authors.initials: S
authors.lastname: Domingues-Montanari
authors.forename: Maite
authors.initials: M
authors.lastname: Mendióroz
authors.forename: Pilar
authors.initials: P
authors.lastname: Delgado
authors.forename: Anna
authors.initials: A
authors.lastname: Rosell
authors.forename: Marc
authors.initials: M
authors.lastname: Ribó
authors.forename: Dolors
authors.initials: D
authors.lastname: Giralt
authors.forename: Manolo
authors.initials: M
authors.lastname: Quintana
authors.forename: Mar
authors.initials: M
authors.lastname: Castellanos
authors.forename: Victor
authors.initials: V
authors.lastname: Obach
authors.forename: Sergi
authors.initials: S
authors.lastname: Martínez
authors.forename: Mari Mar
authors.initials: MM
authors.lastname: Freijo
authors.forename: Jordi
authors.initials: J
authors.lastname: Jiménez-Conde
authors.forename: Jaume
authors.initials: J
authors.lastname: Roquer
authors.forename: Joan
authors.initials: J
authors.lastname: Martí-Fábregas
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Molina
authors.forename: José
authors.initials: J
authors.lastname: Alvarez-Sabín
authors.forename: Joan
authors.initials: J
authors.lastname: Montaner
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002543:Cerebral Hemorrhage / Q000097:blood / Q000453:epidemiology* / Q000235:genetics*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D015994:Incidence; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood / Q000235:genetics*; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D012333:RNA, Messenger / Q000097:blood; D012189:Retrospective Studies; D020521:Stroke / Q000097:blood / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D012333:RNA, Messenger; D010959:Tissue Plasminogen Activator; D020780:Matrix Metalloproteinase 9